CASI Pharmaceuticals (CASIF) EBT Margin (2022 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly EBT Margin came in at 1073.77% in Q4 2025, down 97631.0% YoY from N/an in Q4 2024, and down 209.54% on a QoQ basis from 346.89% in Q3 2025.
CASI Pharmaceuticals (CASIF) EBT Margin (2022 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 4 years of EBT Margin data on file, last reported at 1073.77% in Q4 2025.
- Quarterly EBT Margin fell 97631.0% year-over-year to 1073.77% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 529.15% (down 39138.0% YoY) and the FY2025 annual result came in at 87.87%, up 4553.0% from the prior year.
- EBT Margin fell to 1073.77% in Q4 2025, from 346.89% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 55.98% in Q3 2022 to a low of 1073.77% in Q4 2025.
- A 4-year average of 307.13% and a median of 135.94% in 2025 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin surged 84388 bps — and 2025, when it plunged 97631 bps.
- Tracing CASIF's EBT Margin over 4 years: stood at 979.35% in 2022, then climbed by 4 bps to 941.34% in 2023, then surged by 90 bps to 97.46% in 2024, then sank by 1002 bps to 1073.77% in 2025.
- The last three EBT Margin figures came in at 1073.77% (Q4 2025), 346.89% (Q3 2025), and 265.39% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,073.77% |
| Sep 30, 2025 | -346.89% |
| Jun 30, 2025 | -265.39% |
| Mar 31, 2025 | -165.10% |
| Dec 31, 2024 | -97.46% |
| Sep 30, 2024 | -106.78% |
| Jun 30, 2024 | -217.49% |
| Mar 31, 2024 | -273.48% |
| Dec 31, 2023 | -941.34% |
| Sep 30, 2023 | -57.65% |
| Jun 30, 2023 | -95.16% |
| Mar 31, 2023 | -86.41% |
| Dec 31, 2022 | -979.35% |
| Sep 30, 2022 | -55.98% |
| Jun 30, 2022 | -74.75% |
| Mar 31, 2022 | -77.09% |